spacer
home > > winter 2020 > the elephant in the room
PUBLICATIONS


The Elephant in the Room




Attracting a healthy flow of studies is a pain point for many clinical research sites. Without a reliable pipeline of suitable leads, a research business will flounder. However, the fact is, while other industries frequently employ dedicated business development (BD) specialists to ensure ongoing revenue, the average investigative site does not. Rather, BD is often conducted by research staff with neither the training nor the time to be effective in building the solid foundation required for a successful research site.

Planning Is Key

To be successful, an investigative site must be managed as strategically as any other business, so it is useful to start with a few basic questions: how much growth do I want to see in this business over the next one, three, or five years? How much business is required to make the effort worthwhile and ensure a profitable return on investment? What do I need to do to achieve my goals?

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
About the author


Kurt Mussina brings more than 30 years of international business success to his role at Frenova Renal Research, including a record of leadership and achievement in structuring and orchestrating global BD teams in the contract research services industry. As President, he is responsible for driving Frenova’s global growth and success.
Print this page
Send to a friend
Privacy statement
News and Press Releases

Catalent to Invest $10 Million to Expand High Potency Containment Capabilities For Micronization

Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, today announced that it is investing $10 million in isolator capabilities at its sites in Malvern, Pennsylvania and Dartford, U.K., to expand its micronization capabilities for highly potent drug compounds.
More info >>

White Papers

Bringing more control to temperature-sensitive logistics

UPS Supply Chain Solutions

By 2016, world sales of cold-chain drugs and biologics such as vaccines and blood plasma products will near $240 billion1. The increase has led to a surge in discussion about how to protect these products throughout the transportation logistics cycle. Industry experts are recommending that the term “cold chain” be eliminated from rules, guidance and best-practice documents. “Cold chain” now includes a broader spectrum of temperature ranges, such as controlled room temperature (CRT). This white paper focuses on the initial steps required to establish a temperature-sensitive supply chain.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement